by Truveta Research | Jul 25, 2024 | Research, Research Insights
The analysis was based on a sample of 17,501,982 patients from January 2018 to May 2024. During the study period, 9,271 patients were tested (using CPT code 93922) for the first time and had a diagnosis of peripheral vascular disease/peripheral artery disease...
by Truveta staff | Jul 9, 2024 | News
Today, Truveta kicks off Truveta Symposium, a unique event bringing together leaders from health systems, life sciences, and the government to collaborate on health research with real-world data, embracing generative AI to transform healthcare, and improving patient...
by Truveta Research | Jun 10, 2024 | Research, Research Insights
There are mixed prostate-specific antigen (PSA) screening recommendations for men of varying ages. The objective of this study was to describe variation in first-time PSA values across demographic and SDOH factors. In a study of nearly 4 million men with PSA lab...
by Truveta staff | May 28, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) increased throughout the first quarter of 2024 (+20.9% increase in March 2024 compared to December 2023). First-time prescribing rates (first-time GLP-1 RA prescriptions per total...
by Truveta Research | May 22, 2024 | Research
Norovirus and rotavirus are significant contributors to gastrointestinal infections worldwide, creating risk for patient populations and strain on the healthcare system. Truveta Research evaluated trends in norovirus- and rotavirus-associated hospitalizations overall...